Four patients with supraventricular tachycardia associated with the Wolff-Parkinson-White syndrome were refractory to conventional pharmacological therapy and received aprindine hydrochloride intravenously and orally. Electrophysiological studies disclosed that intravenous aprindine caused increased refractoriness and slowed conduction in the atria, atrioventricular node, ventricles, and accessory pathway. The ability to induce supraventricular tachycardia with timed atrial and ventricular premature stimuli was totally abolished in all 4 patients after intravenous aprindine. Oral aprindine therapy, twice daily thereafter, provided symptomatic relief of the supraventricular tachycardia without significant side effects. Aprindine is useful in the management of supraventricular tachycardia associated with Wolff-Parkinson-White and may offer significant advantages over currently available therapy.
Manifestations of the Wolff -Parkinson -White electrophysiological actions resembling quinidine (WPW) syndrome range from an electrocardio- (Elharrar et al., 1975 ; Steinberg and Greenspan, graphic curiosity in asymptomatic patients to re-1976). current, disabling, and life-threatening arrhythmias
We recently evaluated aprindine hydrochloride in in others. Worsening of congestive heart failure, 4 patients with accessory conduction syndromes precipitation of angina pectoris, and sudden death who were disabled by recurrent supraventricular have been reported in association with the tachy-tachycardia which was refractory to conventional arrhythmias of the WPW syndrome (Wood et al., medical management. In these patients, aprindine 1943; Burchell, 1970) .
was initially administered intravenously during an The principle in management of the supra-intracardiac electrophysiological study. The acute ventricular tachycardia is directed toward interrup-effects of aprindine on conduction, refractoriness, tion of the re-entrant circuit which is usually com-and induction of supraventricular tachycardia were posed of the atrioventricular node, ventricles, studied directly. The patients were then placed on accessory pathway, and the atria. Medical manage-oral therapy and followed with Holter monitoring. ment may be aimed at increasing atrioventricular The response to both intravenous and oral aprinblock (vagal stimulation, digitalis, or propranolol) or dine was nearly complete ablation of the tachyincreasing block in the accessory pathway (quini-arrhythmias in all 4 patients. dine or procainamide). In patients unresponsive to medical therapy, surgical interruption of the atrio-Subjects and methods ventricular node or accessory pathway has been successful (Cobb et al., 1968; Dreifus et al., 1968) . Patients were studied unsedated and post-absorpAprindine (Fasola and Carmichael, 1974) or bursts of tachycardia showed QRS widening and Premature atrial stimulus re-entry zone: the suggested the presence of delta waves which were longest and shortest S, S2 intervals which produced positive in Vl.
early atrial activation by reciprocation using both Electrophysiological study showed evidence for AV node and accessory pathway. accelerated conduction (Fig. 1) . Before aprindine Aprindine hydrochloride (molecular weight, 359) atrial premature beats (from 280 to 500 ms) which was obtained as a lyophilised powder and diluted encountered delay or block in the AV node conto 2 8 mmol/I in saline before infusion. After control ducted with an anomalous pattern identical to the electrophysiological measurements had been made patient's spontaneous premature complexes or aprindine was infused intravenously at a dose of tachycardia. The premature atrial stimulus re-entry 7T8 to 9 7 mmol/kg (2-8 to 3-5 mg/kg) over 15 to 25 zone was found to extend from 280 to 320 ms, at a minutes. The electrophysiological measurements basic cycle length of 600 ms. During the suprawere repeated 30 minutes after the end of the ventricular tachycardia, the QRS widened, the His aprindine infusion. Venous serum samples for potential disappeared, and there was prominent aprindine were obtained from the arm not used for QRS upstroke slurring in Vi. drug infusion and analysed by gas liquid chromatoThese features suggested anterograde bypass graphy (Murphy, 1974) . Aprindine serum levels conduction over a left-sided accessory pathway.
were expressed as [±mol/l of the hydrochloride salt. Thirty minutes after the end of the 150 mg intraAll patients with accessory conduction syn-venous aprindine the serum level was 2-5 umol/1 dromes who were found to be refractory to con-(0 9 ,ug/ml). (Table) . The dose of 150 mg was CASE 2 not exceeded because the patient noted dizziness A 29-year-old white woman presented with a 19-without a change in blood pressure or-heart rate. year history of tachycardia. There was no family The dizziness subsided minutes after stopping the history of cardiovascular disease. During three preginfusion. nancies, she was admitted to hospital repeatedly for Oral aprindine, 25 mg twice daily, was instituted what was described as supraventricular tachycardia. and the patient has not been admitted to hospital or For two years before admission, she noted almost to emergency treatment for 12 months. She daily episodes of rapid heart rate which were largely occasionally notes palpitation of a few seconds dura-unresponsive to vagal manoeuvres. During these tion. Serum levels on oral aprindine have ranged episodes, the patient complained of shortness of from 1-3 to 1*9 ,umol/l (05 to 0 7 ,ug/ml). Holter breath and substernal chest pain. On some occamonitor recordings have confirmed occasional pre-sions, syncopal episodes had resulted in multiple mature beats without sustained supraventricular lacerations. The onset of the tachycardia occurred tachycardia over 14 months.
during sleeping or waking hours, usually with a group.bmj.com on September 21, 2017 -Published by http://heart.bmj.com/ Downloaded from symptomatic duration from 4 to 5 hours, but appeared and ventricular pacing at 5 different basic occasionally lasting as long as 24 hours.
cycle lengths likewise failed to induce re-entry. She had been treated with digitalis, propranolol, Oral aprindine, 50 mg twice daily, gave excellent and quinidine while in hospital. These drugs alone control of arrhythmias with predose serum levels or in combination at various doses did not prevent of 3 9 [±mol/l (1.4 jig/ml). Holter monitoring conthe supraventricular tachycardia.
firmed that occasional premature beats were present Physical examination, chest x-ray film, and echo-without sustained supraventricular tachycardia. cardiogram were normal. The resting electrocardiogram showed sinus rhythm at 70 per minute, CASE 3 a PR interval of 0*14 s, and a QRS duration of A 67-year-old white man was referred for evalua-0-08 s. Holter monitoring before electrophysiological tion of recurrent episodes of palpitation. The patient study revealed frequent episodes of a regular supra-survived a myocardial infarction 16 years before adventricular tachycardia with normal QRS duration, mission. Twelve years before admission, he noted no delta waves, and P waves which were difficult palpitation of abrupt onset associated with weakness, to identify. Multiple previous Holter monitoring diaphoresis, light-headedness, and shortness of recordings disclosed bursts of supraventricular breath. Three years before admission an inferior tachycardia at rates of 140 to 200 per minute, which myocardial infarction was complicated by ventriwere frequently initiated by an atrial premature cular fibrillation. Symptoms of palpitation and weakbeat. At lower rates, the tachycardia was regular, ness without syncope had progressively increased but at higher rates, P waves could not be identified over the 4 to 5 years before admission with up to 4 and gross irregularity developed, raising the ques-episodes a day lasting from minutes to hours. tion of atrial fibrillation.
Digitalis was increased to toxicity. Propranolol was Electrophysiological study (Fig. 2) showed that limited to 80 mg daily because of lethargy, depresthe paroxysmal tachycardia involved .anterograde sion, and dyspnoea. The patient had no benefit conduction through the AV node and bundle-from phenytoin at 300 to 400 mg per day. Quinibranches and retrograde conduction via an accessory dine produced intractable diarrhoea, and procainabundle located in the lateral mitral valve ring. mide caused a skin rash and fever. The patient was Thirty minutes after the end of intravenous in-referred for further evaluation. fusion of 200 mg aprindine serum levels were [5] [6] [7] [8] Physical examination revealed an S4 gallop ,umol/l (2.1 ,uml). Atrial effective refractory period rhythm without cardiomegaly. Chest x-ray film was had increased, while complete retrograde block was normal. The electrocardiogram during sinus rhythm produced in the accessory conduction bundle (ante-showed Q waves in II, III, and aVF, and T wave rograde conduction could never be shown, either inversion in II, III, and aVF and V6 (Fig. 3) . before or after aprindine). Aprindine eliminated the During the frequent tachycardia noted on Holter re-entry zone (190 to 250 ms before aprindine). monitoring, P waves could not be identified, and the After aprindine, the tachycardia could not be pro-ventricular rate was 140 to 160 per minute, regular, duced with any interval of prematurity (Table) . with unchanged QRS complexes. Delta waves were Atrial pacing at 3 progressively more rapid basic absent on most tracings, but on some electrocardiocycle lengths until Wenckebach AV conduction grams delta waves were seen to be positive in lead Vi. Electrophysiological study (Fig. 4) duced 30 minutes after the end of the aprindine diffuse expiratory wheezes. The chest x-ray film infusion. Atrial pacing at four progressively more showed a normal cardiac silhouette and basilar pulrapid basic cycle lengths, to the point of Wencke-monary fibrosis without infiltrates. The resting bach AV block, and ventricular pacing at one basic 12-lead electrocardiogram showed sinus rhythm, cycle length failed to induce re-entry. The serum a PR interval of 0 12 s, minor nonspecific ST-T level at this time was 2-5 ,imol/l (0 9 ji/ml).
changes, a QRS duration of 0-12 s, and a delayed Oral aprindine, 50 mg twice daily, produced initial R upstroke consistent with delta waves. The serum levels of 4-7 [±mol/l (1.7 ,ug/ml) and pre-delta waves were most prominent in II, III, aVF, vented symptomatic attacks of supraventricular V1-3. During the supraventricular tachycardia tachycardia. Holter monitoring during 3 months of ventricular rates ranged from 180 to 215 per follow-up evaluation confirmed the absence of minute, delta waves disappeared, and P waves could supraventricular tachycardia.
not be identified while ST segments became more deeply depressed.
CASE 4
With a repeat electrophysiological study (Fig. 5 ) A 50-year-old white woman had a 35-year history of the presence of an accessory pathway near the paroxysmal supraventricular tachycardia. The epi-lateral mitral ring was confirmed. Atrial premature sodes of supraventricular tachycardia had required beats (S2) from 250-580 ms produced delta waves several admissions to hospital and electrical cardio-and identified a premature atrial stimulus re-entry version, though many episodes of supraventricular zone of 250 to 300 ms (Table) . During the supratachycardia were aborted at home using vagal ventricular tachycardia, delta waves disappeared, manoeuvres. An electrophysiological study at the the HV interval lengthened to normal, and early age of 49 showed a left-sided accessory pathway and retrograde left atrial activation identified a lefta patent foramen ovale. With combinations of sided active accessory pathway. The patient digitalis, propranolol, procainamide, and quinidine, received 200 mg aprindine intravenously over 20 the episodes of supraventricular tachycardia re-minutes. Thirty minutes after the end of the inquiring admission to hospital were reduced from fusion, delta waves were still present at the basic 5 to 6 to 2 to 3 times per year. Higher doses of these cycle length of 600 ms and atrial (S2) prematurity drugs resulted in intolerable gastrointestinal side levels from 580 to 240 ms. However, the premature effects probably associated with a hiatal hernia and atrial stimulus re-entry zone had been abolished and reflux oesophagitis. Symptoms during these periods supraventricular tachycardia could no longer be included near syncope or syncope, chest pain, and induced. Re-entry was not seen with atrial pacing shortness of breath. Her most recent admission to and premature stimuli at two basic cycle lengths hospital was prompted by palpitation, substernal from both right and left atria and ventricular chest pain, and near syncope. During this ad-pacing at two basic cycle lengths. The aprindine mission, she was referred for further evaluation. serum level at this time was 4-7 Fmol/l (1-7 jig/ml).
Her physical examination disclosed obesity and Twenty-four hours later, the patient was placed group.bmj.com on September 21, 2017 -Published by http://heart.bmj.com/ Downloaded from on oral aprindine at a dose of 50 mg every 12 hours. unchanged in 3 patients and appeared to shorten in Predose levels were found to be 5-3 l±mol/l (1.9 1 patient. The apparent shortening of the ventricu-,ug/ml). The patient noted a decrease in the fre-lar refractoriness may represent some instability of quency of palpitation with no sustained tachycardia. catheter position in this 1 patient. The finding of no Repeated 24-hour Holter monitoring during a 5-change in refractoriness in the other 3 patients is month follow-up period confirmed the absence of more consistent with animal studies which show sustained tachycardias.
small dose-related increases in ventricular effective refractory period. Discussion At a constant basic cycle length of 600 ms, the atrial premature beat interval which induced Aprindine is a tertiary amine with local anaesthetic supraventricular tachycardia-the 're-entry zone'-properties making it similar to lignocaine. However, was abolished in all 4 patients. The increased conthe half-life (20 to 30 hours) is much longer, and duction time and refractoriness of the atria, the oral absorption confers effective antiarrhythmic accessory pathway, and possibly the AV node, activity (Fasola and Carmichael, 1974 ; Murphy, appear to account for the effective results with 1974). Therapeutic blood levels have been esti-aprindine. mated to be 2*8-5*6 ,umol/l (1-2 jig/ml) (Fasola and When begun on oral therapy, all patients became Carmichael, 1974) . The side effects are primarily in asymptomatic from their previously disabling central nervous system and include dizziness, supraventricular tachycardia. The symptomatic tremor, nystagmus, and ataxia. These side effects improvement was subsequently confirmed by disappear when the dose is reduced or stopped.
repeated Holter monitoring while the patients were Experimental studies in animals have indicated ambulatory. that aprindine increased the effective refractory It is noteworthy that all these patients had leftperiod and conduction time in the atrium, AV node, sided accessory pathways. Since the study group is and distal conduction system (Elharrar et al., 1975 ; small and no refractory WPW patients were eli- Steinberg and Greenspan, 1976) . minated from this study it cannot be determined Acute administration of aprindine increased whether or not this finding is coincidental or repreatrial effective refractory period in 3 of the 4 sents some special predilection of patients with leftpatients (Table) . Measurement of AV node anterc-sided pathways to drug resistance. grade effective refractory period was limited by
In man, aprindine has been used primarily to atrial effective refractory period in 2 cases, though control ventricular arrhythmias (Kesteloot et al., AV node effective refractory period unequivocally 1973; Hagemeijer et al., 1974) . Aprindine has been increased in 1 patient. AV node conduction time used less frequently for supraventricular tachy-(AH interval) increased significantly in 3 of the 4 cardia, though a few patients have been reported in patients.
whom it was effective for supraventricular tachyAnterograde accessory pathway conduction was cardia associated with WPW syndrome (Kesteloot seen in only cases 1 and 4. After aprindine the et al., 1973; Kesteloot, 1974; Fasola and Car- anterograde refractoriness increased in 1 of these 2 michael, 1974; Neuss and Schlepper, 1974;  patients (case 1). Palma-Gamiz et al., 1974 ). Aprindine appears After aprindine, retrograde refractoriness of the effective against the refractory supraventricular accessory pathway was increased or complete block tachycardia associated with the WPW syndrome was produced in 2 of the 4 patients (cases 1 and 4) because it eliminates re-entry zones by slowing In the remaining 2 cases, right ventricular effective conduction and increasing refractoriness in the refractory period was reached before that of the cardiac tissues which initiate or perpetuate the accessory pathway. supraventricular tachycardia. While similar changes The His-Purkinje conduction time (HV interval) may be seen with quinidine and procainamide, the and QRS duration increased transiently in 3 of the 4 magnitude of the effect by aprindine on different patients. These intervals returned toward normal parts of the re-entrant loop may permit better by the end of the study, suggesting that aprindine arrhythmia control at doses which do not produce should be given as a slow infusion to avoid a unacceptable side effects. potential dose-related distal conduction delay. In
Other new antiarrhythmic agents, such as amiocase 4, at the basic cycle length of 600 ms, a delta darone (Rosenbaum et al., 1974) , have also been wave was present before aprindine and not after successfully used in WPW patients. The mechanism aprindine, producing a QRS shortening and HV of action of amiodarone is similar to aprindine in lengthening caused by more normal antegrograde slowing conduction but has other effects such as a conduction. The refractoriness of the ventricles was coronary vasodilatation and catecholamine anta-
